Department of Internal Medicine, Division of Cardiology, Washington Hospital Center, 10 Irving Street NW, Washington, DC 20010, USA.
EuroIntervention. 2009 Dec 15;5 Suppl F:F36-42. doi: 10.4244/EIJV5IFA6.
Advances in coronary stent technology, including refinement of the stent alloy, strut thickness, stent geometry, passive coating, and drug elution, have dramatically enhanced the safety and efficacy of percutaneous coronary intervention (PCI) with stenting. Stents are currently used in over 90% of coronary interventions and the use of drug-eluting stents (DES) has been disseminated to more complex lesion subsets such as total occlusions, long lesions, bifurcation lesions, and for patients with acute myocardial infarction. DES continue to demonstrate reduction in restenosis and the need for repeat revascularisation but are associated with delayed healing and re-endothelialisation, which have led to an increased rates of late stent thrombosis, dependency on prolonged dual antiplatelet therapy, impaired in-vessel reactivity, and chronic inflammation. As scientists and clinicians better understand the mechanism for late restenosis and stent thrombosis, a variety of solutions in regard to stent technology have been proposed, including stent coating, polymer bioabsorption, and fully biodegradable stents. Bare metal stents were improved by the reduction of strut thickness, changes in stent geometry, and the addition of passive coating, which lead to improvements in efficacy and reduction of restenosis. In addition, there is continued improvement in the polymer technology for DES, including new biocompatible, thinner durable polymers, and bioabsorbable polymers that completely bioabsorb within 3-12 months after stent implantation. These features potentially minimise the chronic inflammatory response and late stent thrombosis. Finally, fully bioabsorbable stents, both polymeric and metallic, continue to be developed in order to eliminate any late stenting effects and potentially may enable complete vessel restoration. This manuscript will discuss the wide variety of new stent technologies and compare and contrast durable metallic and polymeric stents to current biodegradable stent technology.
冠状动脉支架技术的进步,包括支架合金、支架支柱厚度、支架几何形状、被动涂层和药物洗脱的改进,极大地提高了经皮冠状动脉介入治疗(PCI)和支架置入的安全性和疗效。支架目前在超过 90%的冠状动脉介入中使用,药物洗脱支架(DES)的使用已经扩展到更复杂的病变亚组,如完全闭塞、长病变、分叉病变,以及用于急性心肌梗死的患者。DES 继续显示出减少再狭窄和需要再次血运重建的效果,但与延迟愈合和再内皮化有关,这导致晚期支架血栓形成的发生率增加,对延长双联抗血小板治疗的依赖,血管内反应性受损,以及慢性炎症。随着科学家和临床医生更好地了解晚期再狭窄和支架血栓形成的机制,已经提出了各种关于支架技术的解决方案,包括支架涂层、聚合物生物吸收和完全可生物降解支架。通过减少支架支柱厚度、改变支架几何形状和添加被动涂层,改善了裸金属支架的效果,减少了再狭窄的发生。此外,DES 的聚合物技术也在不断改进,包括新的生物相容性、更薄的耐用聚合物和完全在支架植入后 3-12 个月内生物吸收的可生物吸收聚合物。这些特性潜在地最小化了慢性炎症反应和晚期支架血栓形成。最后,继续开发完全可生物吸收的支架,包括聚合物和金属支架,以消除任何晚期支架效应,并可能使血管完全恢复。本文将讨论各种新的支架技术,并比较和对比耐用金属和聚合物支架与当前的可生物降解支架技术。